The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist

Molecular and Cellular Endocrinology

Volumn 214, Issue 1-2, 2004, Pages 27-37

  Rebuffat, Alexandre G ^a   Tam, Steven ^b   Nawrocki, Andrea R ^a   Baker, Michael E ^b   Frey, Brigitte M ^a   Frey, Felix J ^a   Odermatt, Alex ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

11 Hydroxysteroid dehydrogenase; Cortisol; Dexamethasone; Glucocorticoid receptor; Mineralocorticoid receptor

Indexed keywords

CORTISONE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLON; DRUG BINDING; DRUG EFFECT; HUMAN; HUMAN CELL; KIDNEY; PRIORITY JOURNAL; RECEPTOR BINDING; REPORTER GENE; TUMOR CELL;

EID: 1142285512     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.11.027     Document Type: Article

References (36)

1. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., Evans R.M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 237:1987;268-275.
2. Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (Lond.). 94:1998;557-572.
3. Best R., Nelson S.M., Walker B.R. Dexamethasone and 11- dehydrodexamethasone as tools to investigate the isozymes of 11 beta-hydroxysteroid dehydrogenase in vitro and in vivo. J. Endocrinol. 153:1997;41-48.
4. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., Consler T.G., Parks D.J., Stewart E.L., Willson T.M., Lambert M.H., Moore J.T., Pearce K.H., Xu H.E. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 110:2002;93-105.
5. Carey K.L., Richards S.A., Lounsbury K.M., Macara I.G. Evidence using a green fluorescent protein-glucocorticoid receptor chimera that the Ran/TC4 GTPase mediates an essential function independent of nuclear protein import. J. Cell Biol. 133:1996;985-996.
6. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
7. Diederich S., Hanke B., Oelkers W., Bahr V. Metabolism of dexamethasone in the human kidney: nicotinamide adenine dinucleotide-dependent 11beta-reduction. J. Clin. Endocrinol. Metab. 82:1997;1598-1602.
8. Diederich S., Eigendorff E., Burkhardt P., Quinkler M., Bumke-Vogt C., Rochel M., Seidelmann D., Esperling P., Oelkers W., Bahr V. 11beta- hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J. Clin. Endocrinol. Metab. 87:2002;5695-5701.
9. Escher G., Frey F.J., Frey B.M. 11 beta-Hydroxysteroid dehydrogenase accounts for low prednisolone/prednisone ratios in the kidney. Endocrinology. 135:1994;101-106.
10. Fejes-Toth G., Pearce D., Naray-Fejes-Toth A. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2973-2978.
11. Ferrari P., Smith R.E., Funder J.W., Krozowski Z.S. Substrate and inhibitor specificity of the cloned human 11 beta-hydroxysteroid dehydrogenase type 2 isoform. Am. J. Physiol. 270:1996;E900-E904.
12. Goodman-Gilman, A. (Ed.), 1996. The Pharmacological Basis of Therapeutics. McGraw-Hill, New York.
13. Hellal-Levy C., Couette B., Fagart J., Souque A., Gomez-Sanchez C., Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett. 464:1999;9-13.
14. Hundertmark S., Buhler H., Rudolf M., Weitzel H.K., Ragosch V. Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells. J. Endocrinol. 155:1997;171-180.
15. Kauppi B., Jakob C., Farnegardh M., Yang J., Ahola H., Alarcon M., Calles K., Engstrom O., Harlan J., Muchmore S., Ramqvist A.K., Thorell S., Ohman L., Greer J., Gustafsson J.A., Carlstedt-Duke J., Carlquist M. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 278:2003;22748-22754.
16. Li K.X., Obeyesekere V.R., Krozowski Z.S., Ferrari P. Oxoreductase and dehydrogenase activities of the human and rat 11beta-hydroxysteroid dehydrogenase type 2 enzyme. Endocrinology. 138:1997;2948-2952.
17. Lim-Tio S.S., Keightley M.C., Fuller P.J. Determinants of specificity of transactivation by the mineralocorticoid or glucocorticoid receptor. Endocrinology. 138:1997;2537-2543.
18. Lombes M., Kenouch S., Souque A., Farman N., Rafestin-Oblin M.E. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Endocrinology. 135:1994;834-840.
19. Miesfeld R., Rusconi S., Godowski P.J., Maler B.A., Okret S., Wikstrom A.C., Gustafsson J.A., Yamamoto K.R. Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA. Cell. 46:1986;389-399.
20. Morita H., Zhou M., Foecking M.F., Gomez-Sanchez E.P., Cozza E.N., Gomez-Sanchez C.E. 11 beta-Hydroxysteroid dehydrogenase type 2 complementary deoxyribonucleic acid stably transfected into Chinese hamster ovary cells: specific inhibition by 11 alpha-hydroxyprogesterone. Endocrinology. 137:1996;2308-2314.
21. Mune T., Morita H., Suzuki T., Takahashi Y., Isomura Y., Tanahashi T., Daido H., Yamakita N., Deguchi T., Sasano H., White P.C., Yasuda K. Role of local 11 beta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas. J. Clin. Endocrinol. Metab. 88:2003;864-870.
22. N'Gankam V., Uehlinger D., Dick B., Frey B.M., Frey F.J. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney Int. 61:2002;1859-1866.
23. Odermatt A., Arnold P., Frey F.J. The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. J. Biol. Chem. 276:2001;28484-28492.
24. Odermatt A., Arnold P., Stauffer A., Frey B.M., Frey F.J. The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J. Biol. Chem. 274:1999;28762-28770.
25. Oelkers W., Buchen S., Diederich S., Krain J., Muhme S., Schoneshofer M. Impaired renal 11 beta-oxidation of 9 alpha-fluorocortisol: an explanation for its mineralocorticoid potency. J. Clin. Endocrinol. Metab. 78:1994;928-932.
26. Rabbitt E.H., Ayuk J., Boelaert K., Sheppard M.C., Hewison M., Stewart P.M., Gittoes N.J. Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene. 22:2003;1663-1667.
27. Ray D.W., Suen C.S., Brass A., Soden J., White A. Structure/function of the human glucocorticoid receptor: tyrosine 735 is important for transactivation. Mol. Endocrinol. 13:1999;1855-1863.
28. Rogerson F.M., Dimopoulos N., Sluka P., Chu S., Curtis A.J., Fuller P.J. Structural determinants of aldosterone binding selectivity in the mineralocorticoid receptor. J. Biol. Chem. 274:1999;36305-36311.
29. Satoh K., Galli I., Ariga H. Effect of drugs on gene expression in mammalian cells: a highly efficient procedure to test large numbers of samples. Nucleic Acids Res. 21:1993;4429-4430.
30. Siebe H., Baude G., Lichtenstein I., Wang D., Buhler H., Hoyer G.A., Hierholzer K. Metabolism of dexamethasone: sites and activity in mammalian tissues. Ren. Physiol. Biochem. 16:1993;79-88.
31. Stewart P.M., Krozowski Z.S. 11 beta-Hydroxysteroid dehydrogenase. Vitam. Horm. 57:1999;249-324.
32. Tulpule A., Sherrod A., Dharmapala D., Young L.L., Espina B.M., Sanchez M.N., Gill P.S., Levine A.M. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk. Res. 26:2002;121-127.
33. Wei P., Ahn Y.I., Housley P.R., Alam J., Vedeckis W.V. Modulation of hormone-dependent glucocorticoid receptor function using a tetracycline- regulated expression system. J. Steroid. Biochem. Mol. Biol. 64:1998;1-12.
34. White P.C., Mune T., Agarwal A.K. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr. Rev. 18:1997;135-156.
35. Yoshikawa N., Makino Y., Okamoto K., Morimoto C., Makino I., Tanaka H. Distinct interaction of cortivazol with the ligand binding domain confers glucocorticoid receptor specificity: cortivazol is a specific ligand for the glucocorticoid receptor. J. Biol. Chem. 277:2002;5529-5540.
36. Zhao J.Y., Ikeguchi M., Eckersberg T., Kuo M.T. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology. 133:1993;521-528.